Abstract
Some epidemiological studies suggest that increased consumption of anthocyanins is associated with lower risk of cardiovascular disease (CVD) and hypertension. Also, high consumption of anthocyanin-rich fruit, such as berries, is associated with a lower risk of developing type 2 diabetes (T2D). In this review, we briefly yet critically assess the available evidence in support of an anti-diabetic role of anthocyanins derived from berries, especially bilberry (Vaccinium myrtillus L., also known as European blueberry, whortleberry, huckleberry and blaeberry) and blueberry (Vaccinium corymbosum, native to the United States). Further, cellular and molecular mechanisms are discussed and the “pharma-nutrition” use of anthocyanin-based preparations for the prevention and treatment of T2D is examined. We conclude that animal and in vitro studies strongly indicate that bilberry and blueberry have the potential to ameliorate T2D and its cardio-metabolic outcomes. However, appropriate clinical trials are lacking and will eventually clarify whether these foods (either as such or formulated as nutraceuticals) might be added to the current pharma-nutritional armamentarium.
Keywords: Bilberry, blueberry, anthocyanins, diabetes, chronic low-grade inflammation, nutraceuticals, pharma-nutrition, bioavailability.
Current Pharmaceutical Design
Title:A Brief Review of Blue- and Bilberries’ Potential to Curb Cardio-Metabolic Perturbations: Focus on Diabetes
Volume: 23 Issue: 7
Author(s): M. Carmen Crespo and Francesco Visioli*
Affiliation:
- Department of Molecular Medicine, University of Padova, Viale G. Colombo 3, 35121 Padova,Italy
Keywords: Bilberry, blueberry, anthocyanins, diabetes, chronic low-grade inflammation, nutraceuticals, pharma-nutrition, bioavailability.
Abstract: Some epidemiological studies suggest that increased consumption of anthocyanins is associated with lower risk of cardiovascular disease (CVD) and hypertension. Also, high consumption of anthocyanin-rich fruit, such as berries, is associated with a lower risk of developing type 2 diabetes (T2D). In this review, we briefly yet critically assess the available evidence in support of an anti-diabetic role of anthocyanins derived from berries, especially bilberry (Vaccinium myrtillus L., also known as European blueberry, whortleberry, huckleberry and blaeberry) and blueberry (Vaccinium corymbosum, native to the United States). Further, cellular and molecular mechanisms are discussed and the “pharma-nutrition” use of anthocyanin-based preparations for the prevention and treatment of T2D is examined. We conclude that animal and in vitro studies strongly indicate that bilberry and blueberry have the potential to ameliorate T2D and its cardio-metabolic outcomes. However, appropriate clinical trials are lacking and will eventually clarify whether these foods (either as such or formulated as nutraceuticals) might be added to the current pharma-nutritional armamentarium.
Export Options
About this article
Cite this article as:
Crespo Carmen M. and Visioli Francesco*, A Brief Review of Blue- and Bilberries’ Potential to Curb Cardio-Metabolic Perturbations: Focus on Diabetes, Current Pharmaceutical Design 2017; 23 (7) . https://dx.doi.org/10.2174/1381612822666161010120523
DOI https://dx.doi.org/10.2174/1381612822666161010120523 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Issues and Progress in Isolation of Susceptibility Genes of Essential Hypertension
Current Hypertension Reviews Prevalence and Prognostic Value of Depression and Anxiety in Patients with Diabetic Foot Ulcers and Possibilities of their Treatment
Current Diabetes Reviews Type 1 11 β-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanisms of Medial Arterial Calcification in Diabetes
Current Pharmaceutical Design Anesthesia Issues in Central Nervous System Disorders
Current Aging Science Current Strategies and Future Perspective for the Effective Treatment of Diabetic Retinopathy
Current Drug Therapy Coarctation of the Aorta - The Current State of Surgical and Transcatheter Therapies
Current Cardiology Reviews The Role of 5-HT1A Receptor in Cancer as a New Opportunity in Medicinal Chemistry
Current Medicinal Chemistry Protective Effect of Urate Oxidase on Uric Acid Induced-Monocyte Apoptosis
Current Drug Discovery Technologies Flower Pollen Extract in Association with Vitamins (Deprox 500®) Versus Serenoa repens in Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Comparative Analysis of Two Different Treatments
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Fluid and Electrolyte Disorders in the Newborn: Sodium and Potassium
Current Pediatric Reviews Serum Interleukin-33 as a Biomarker in Predicting Neonatal Sepsis in Premature Infants
Combinatorial Chemistry & High Throughput Screening Racing of the Biological Pacemaker
Recent Patents on DNA & Gene Sequences Is Impaired Flow-Mediated Dilatation of the Brachial Artery a Cardiovascular Risk Factor?
Current Vascular Pharmacology Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Biological Activity of Cytokines: An Evolutionary Perspective
Current Pharmaceutical Design Pleiotropic Effects of ARB on Dyslipidemia
Current Vascular Pharmacology Editorial [Hot Topic: Recent Progress in the Development of Anti-Diabetic Drugs (Guest Editor: J. Eckel)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry